ArticleInvestigative ophthalmology & visual science2026
Functional and Metabolic Abnormalities in Primary Visual Cortex and Frontal Eye Fields and Candidate Biomarkers of Acute Acquired Comitant Esotropia.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate functional and metabolic changes in the primary visual cortex (V1) and frontal eye fields (FEFs) of patients with acute acquired comitant esotropia (AACE), identify potential biomarkers, and explore their associations with clinical features. Methods: Fifteen patients with AACE and 15 healthy controls underwent resting-state functional magnetic resonance imaging and single-voxel ¹H-magnetic resonance spectroscopy. Regional homogeneity (ReHo) and amplitude of low-frequency fluctuation (ALFF) in V1 and FEF, as well as the absolute concentrations of N-acetylaspartate (NAA), aspartate (Asp), glutamate (Glu), and glutathione (GSH) in V1 and FEF, were compared between the two groups and selected via LASSO regression. Results: Compared with controls, the AACE group exhibited significantly increased ReHo and ALFF in both V1 and FEF (all false discovery rate [FDR] q < 0.05). ReHo levels in V1 and FEF significantly discriminated patients with AACE from controls in receiver operating characteristic (ROC) analysis (area under the curve = 0.77-0.83, all FDR q < 0.05). Asp and NAA levels in V1 were significantly lower in the AACE group than those in the control group and had significant discrimination by ROC analysis (all q < 0.05). Logistic least absolute shrinkage and selection operator regressions identified ReHo in FEF and V1, ALFF in FEF, NAA and Asp levels in V1, and GSH and NAA levels in FEF as potential biomarkers of AACE. Conclusions: The pathogenesis of AACE might involve dual neural mechanisms: neuronal metabolism alteration and adaptive function upregulation within the visual cortex and oculomotor cortical regions. ReHo in V1 and FEF could serve as core functional biomarkers, and NAA and Asp levels in V1 and NAA and GSH levels in FEF might serve as core metabolic biomarkers of AACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.